Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.

Cossu-Rocca P, Contini M, Uras MG, Muroni MR, Pili F, Carru C, Bosincu L, Massarelli G, Nogales FF, De Miglio MR.

Int J Gynecol Pathol. 2012 Nov;31(6):570-9. doi: 10.1097/PGP.0b013e31824fe289.

PMID:
23018215
2.

Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.

Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS.

Hum Pathol. 2005 Mar;36(3):242-9.

PMID:
15791568
3.

Analysis of epidermal growth factor receptor (EGFR) status in endometrial stromal sarcoma.

Capobianco G, Pili F, Contini M, De Miglio MR, Marras V, Santeufemia DA, Cherchi C, Dessole M, Cherchi PL, Cossu-Rocca P.

Eur J Gynaecol Oncol. 2012;33(6):629-32.

PMID:
23327060
4.

Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.

Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, Gronchi A, Pastorino U, Pierotti MA, Pilotti S.

J Pathol. 2007 Jun;212(2):227-35.

PMID:
17471466
5.

Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.

Liegl B, Gülly C, Reich O, Nogales FF, Beham A, Regauer S.

Histopathology. 2007 Mar;50(4):448-52.

PMID:
17448020
6.

Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.

Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.

Pathol Res Pract. 2007;203(3):127-34. Epub 2007 Feb 12.

PMID:
17298867
7.

Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.

Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.

Gynecol Oncol. 2004 Oct;95(1):32-6.

PMID:
15385107
8.

PDGFR-alpha as a potential therapeutic target in uterine sarcomas.

Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD.

Gynecol Oncol. 2007 Mar;104(3):524-8. Epub 2006 Oct 17.

PMID:
17049587
9.

Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.

Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F.

Breast Cancer Res. 2005;7(5):R788-95. Epub 2005 Aug 1.

10.
11.

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Zheng S, Chen LR, Wang HJ, Chen SZ.

Hepatogastroenterology. 2007 Dec;54(80):2285-90.

PMID:
18265649
12.

Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases.

Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E, Kobayashi H, Wake N, Tsuneyoshi M.

Am J Surg Pathol. 2008 Aug;32(8):1228-38. doi: 10.1097/PAS.0b013e31816a3b42.

PMID:
18580489
13.

Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.

Schirosi L, Lantuejoul S, Cavazza A, Murer B, Yves Brichon P, Migaldi M, Sartori G, Sgambato A, Rossi G.

Am J Surg Pathol. 2008 Nov;32(11):1627-42. doi: 10.1097/PAS.0b013e31817a8a89.

PMID:
18753943
14.

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.

Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.

Cancer. 2003 Aug 15;98(4):758-64.

15.

Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.

Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S.

Clin Cancer Res. 2006 Dec 1;12(23):6920-8.

16.

Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.

Chu S, Alexiadis M, Fuller PJ.

Gynecol Oncol. 2008 Jan;108(1):182-90. Epub 2007 Oct 29.

PMID:
18028988
17.

Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.

Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.

Reprod Sci. 2008 Sep;15(7):673-7. doi: 10.1177/1933719108317584. Epub 2008 May 20.

PMID:
18492696
18.

Oncogene alterations in endometrial carcinosarcomas.

Biscuola M, Van de Vijver K, Castilla MÁ, Romero-Pérez L, López-García MÁ, Díaz-Martín J, Matias-Guiu X, Oliva E, Palacios Calvo J.

Hum Pathol. 2013 May;44(5):852-9. doi: 10.1016/j.humpath.2012.07.027. Epub 2012 Nov 28.

PMID:
23199529
19.

Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.

Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, Ueland FR, van Nagell JR, Ahmed MM, Lele SM.

Gynecol Oncol. 2003 Oct;91(1):9-14.

PMID:
14529657
20.

PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.

Rossi G, Valli R, Bertolini F, Marchioni A, Cavazza A, Mucciarini C, Migaldi M, Federico M, Trentini GP, Sgambato A.

Histopathology. 2005 May;46(5):522-31.

PMID:
15842634

Supplemental Content

Support Center